Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: Andrew Abrams who wrote (738)	10/28/1998 12:13:00 AM
From: John Binford, Jr.	Read Replies (1) \| Respond to of 1754

The patent issue doesn't affect Visx's profits in the near term. The patent issue has no bearing on Visx's right to collect a per procedure fee in the U.S. for use of Visx lasers. Visx also has many key U.S. patents not currently under challenge by the FTC. The only issue is whether or not Visx can enforce their patents on newcomers here in the U.S. If enforcement were a certainty, Visx stock would be > $100/sh right now. The market has discounted Visx because of the uncertainty, however, Visx earnings are continuing to grow. Soon Visx will obtain Hyperopia approval in the U.S. and hopefully PRK approval in Japan. I feel Visx is attractively priced at the current level.